Key facts
- It has raised $48.5M; the latest was Seed Round ($48.5M) in Apr 2025.
- Notable investors include Brabantse Ontwikkelings Maatschappij, EQT Life Sciences, Kurma Partners, MaasInvest, BioGeneration Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Avidicure
- ·The full record, as it builds
Funding rounds
No funding rounds for Avidicure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avidicure
Developer of a dual agonistic, multifunctional antibody modality designed to engage immune cells for targeted cancer treatment. The company offers avidity-engineered antibodies with localized activation in tumors, enabling oncology researchers to support immune responses while limiting off-target effects.
- Sector
- Healthcare
- HQ
- Oegstgeest, Netherlands
- Founded
- 2022
- Employees
- 35
- Website
- avidicure.com/
- Ownership
- Privately Held (backing)
Avidicure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avidicure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avidicure in its N-PORT filings yet. We sweep new filings monthly.